Healthcare innovation and biotechnology are emerging as highly promising sectors for investors. The recent rate cut in September has enhanced the outlook for these industries, while advancements in research and development (R&D), particularly fueled by artificial intelligence (AI), are paving the way for groundbreaking drug discoveries. As uncertainty in equities rises, health and biotech exchange-traded funds (ETFs) are becoming increasingly attractive options. In this context, investors may want to explore how active investing strategies can outperform passive approaches in the biotech sector.<\/span><\/p>\n See more: Rising Active ETF TCAF Up Half a Billion Over Last Week<\/a> Contrary to the common perception of biotech as a field dominated by lab-coated scientists peering through microscopes, the reality is much more dynamic. Recent analysis from T. Rowe Price highlights that biotech has evolved significantly since the mapping of the human genome two decades ago. Investment analyst <\/span>John Hall,<\/span><\/a> Ph.D., identifies four major modalities that are driving new drug discoveries in the biotech landscape: gene therapy, gene editing, oligonucleotide therapies, and targeted protein degradation.<\/span><\/p>\n What do these modalities entail? Gene therapy aims to tackle serious health issues caused by even a single error in DNA sequences. By modifying viruses, scientists can deliver healthy versions of faulty genes to affected cells.<\/span><\/p>\n Gene editing employs CRISPR techniques to cut and modify gene strands, allowing for the insertion of new genes or alterations to existing ones. Oligonucleotide therapies focus on introducing synthetic DNA or RNA to change protein production. Lastly, the innovative targeted protein degradation approach utilizes the cell\u2019s natural quality control mechanisms to eliminate damaged proteins, often resulting from genetic issues.<\/span><\/p>\n These modalities open up new avenues for drug development in diverse areas, including Alzheimer\u2019s disease and heart conditions. The recent rate cuts also facilitate the borrowing needed to fund R&D before drug revenues materialize, while simultaneously boosting mergers and acquisitions (M&A) activity that supports biotech investments.<\/span><\/p>\n Active management, which leverages in-depth analyst expertise, can outperform passive strategies by identifying firms with the most promising prospects. More importantly, active management can mitigate the performance dispersion often seen in index funds. As Hall points out, the S&P Biotechnology Select Industry Index had lost approximately 10% of its trailing 12-month value as of June 30 this year. In contrast, the top 10 performers within that index delivered average returns of 145%.<\/span><\/p>\n Active healthcare and biotech ETFs can capitalize on these strong performers while steering clear of underperforming stocks that drag down index funds. With overall equity markets becoming increasingly uncertain, drug R&D presents a significant opportunity for growth. The T. Rowe Price Health Care ETF (TMED)<\/a> offers exposure to healthcare companies, including leading biotech firms. With a fee of 44 basis points, this fund stands out for its fundamental research-driven active approach.<\/span><\/p>\n
<\/span><\/p>\n
![\"\"\/](\"https:\/\/www.etftrends.com\/wp-content\/themes\/smart-mag\/images\/newsletter-embeds\/newsletter-first.jpg\")
\n <\/div>\n